VRTX – Vertex Pharmaceuticals Incorporated
VRTX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.97
Margin Of Safety %
9
Put/Call OI Ratio
1.16
EPS Next Q Diff
0.01
EPS Last/This Y
3.21
EPS This/Next Y
2.62
Price
496.02
Target Price
563.83
Analyst Recom
1.56
Performance Q
16.72
Upside
-23.8%
Beta
0.3
Ticker: VRTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | VRTX | 480.49 | 0.89 | 3.07 | 46093 |
| 2026-07-14 | VRTX | 476.53 | 0.92 | 0.75 | 47671 |
| 2026-07-15 | VRTX | 477.2 | 0.91 | 0.96 | 48378 |
| 2026-07-16 | VRTX | 486.2 | 0.92 | 2.96 | 49529 |
| 2026-07-17 | VRTX | 485.65 | 0.99 | 3.92 | 52289 |
| 2026-07-20 | VRTX | 480.61 | 1.11 | 1.43 | 45578 |
| 2026-07-21 | VRTX | 481.85 | 1.12 | 2.08 | 46827 |
| 2026-07-22 | VRTX | 472.74 | 1.12 | 2.91 | 47050 |
| 2026-07-23 | VRTX | 473.17 | 1.12 | 1.96 | 47832 |
| 2026-07-24 | VRTX | 477.29 | 1.14 | 5.58 | 48886 |
| 2026-07-27 | VRTX | 478.84 | 1.23 | 1.00 | 48846 |
| 2026-07-28 | VRTX | 490.32 | 1.20 | 2.67 | 50814 |
| 2026-07-29 | VRTX | 483.45 | 1.21 | 1.35 | 51183 |
| 2026-07-30 | VRTX | 481.77 | 1.19 | 1.94 | 51574 |
| 2026-07-31 | VRTX | 476.98 | 1.20 | 0.81 | 51913 |
| 2026-08-03 | VRTX | 470.36 | 1.16 | 1.28 | 47741 |
| 2026-08-04 | VRTX | 478.82 | 1.21 | 1.17 | 54661 |
| 2026-08-05 | VRTX | 485.05 | 1.19 | 0.60 | 54306 |
| 2026-08-06 | VRTX | 484.27 | 1.16 | 2.00 | 56049 |
| 2026-08-07 | VRTX | 496.21 | 1.16 | 1.09 | 57080 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | VRTX | 480.28 | 4.5 | 522.5 | 19.00 |
| 2026-07-14 | VRTX | 476.48 | 4.6 | 537.5 | 18.99 |
| 2026-07-15 | VRTX | 477.17 | 4.4 | 591.4 | 18.98 |
| 2026-07-16 | VRTX | 486.11 | 4.4 | 687.1 | 18.98 |
| 2026-07-17 | VRTX | 485.58 | 4.8 | 572.7 | 19.00 |
| 2026-07-20 | VRTX | 480.42 | 4.8 | 517.7 | 19.00 |
| 2026-07-21 | VRTX | 481.89 | 5.0 | 593.9 | 18.96 |
| 2026-07-22 | VRTX | 472.73 | 5.0 | 470.4 | 18.96 |
| 2026-07-23 | VRTX | 473.16 | 5.0 | 584.8 | 18.96 |
| 2026-07-24 | VRTX | 477.42 | 5.0 | 629.0 | 18.96 |
| 2026-07-27 | VRTX | 478.84 | 5.0 | 595.1 | 18.96 |
| 2026-07-28 | VRTX | 490.38 | 5.0 | 710.4 | 18.96 |
| 2026-07-29 | VRTX | 483.47 | 5.0 | 499.1 | 18.96 |
| 2026-07-30 | VRTX | 481.80 | 5.0 | 560.0 | 18.96 |
| 2026-07-31 | VRTX | 476.89 | 5.0 | 522.1 | 18.96 |
| 2026-08-03 | VRTX | 470.61 | 5.0 | 501.7 | 18.96 |
| 2026-08-04 | VRTX | 470.61 | 5.0 | 501.7 | 18.96 |
| 2026-08-05 | VRTX | 484.79 | 0.3 | 649.1 | 18.98 |
| 2026-08-06 | VRTX | 484.11 | 0.3 | 570.0 | 18.98 |
| 2026-08-07 | VRTX | 496.02 | -2.4 | 602.8 | 18.67 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | VRTX | -24.17 | -1.08 | 1.95 |
| 2026-07-14 | VRTX | -24.17 | -1.08 | 1.95 |
| 2026-07-15 | VRTX | -24.17 | -1.08 | 1.95 |
| 2026-07-16 | VRTX | -24.17 | -1.08 | 1.95 |
| 2026-07-17 | VRTX | -24.17 | -1.08 | 1.95 |
| 2026-07-20 | VRTX | -24.17 | 0.27 | 1.95 |
| 2026-07-21 | VRTX | -24.17 | 0.27 | 1.95 |
| 2026-07-22 | VRTX | -24.17 | 0.27 | 1.95 |
| 2026-07-23 | VRTX | -24.17 | 0.27 | 1.95 |
| 2026-07-24 | VRTX | -24.17 | 0.27 | 1.95 |
| 2026-07-27 | VRTX | -24.17 | -1.26 | 1.97 |
| 2026-07-28 | VRTX | -24.17 | -1.26 | 1.97 |
| 2026-07-29 | VRTX | -24.17 | -1.26 | 1.97 |
| 2026-07-30 | VRTX | -22.54 | -1.26 | 1.97 |
| 2026-07-31 | VRTX | -22.54 | -1.26 | 1.97 |
| 2026-08-03 | VRTX | -22.54 | -1.17 | 1.97 |
| 2026-08-04 | VRTX | -22.54 | -1.17 | 1.97 |
| 2026-08-05 | VRTX | -22.54 | -1.17 | 1.97 |
| 2026-08-06 | VRTX | -22.54 | -1.17 | 1.97 |
| 2026-08-07 | VRTX | -22.57 | -1.17 | 1.97 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
4.73
Avg. EPS Est. Current Quarter
4.68
Avg. EPS Est. Next Quarter
4.74
Insider Transactions
-22.57
Institutional Transactions
-1.17
Beta
0.3
Average Sales Estimate Current Quarter
3395
Average Sales Estimate Next Quarter
3508
Fair Value
539.15
Quality Score
87
Growth Score
96
Sentiment Score
72
Actual DrawDown %
7
Max Drawdown 5-Year %
-29.1
Target Price
563.83
P/E
28.86
Forward P/E
23.36
PEG
2.09
P/S
9.9
P/B
6.21
P/Free Cash Flow
33.12
EPS
17.19
Average EPS Est. Cur. Y
18.67
EPS Next Y. (Est.)
21.29
Target Price Estimates Raised
8
Target Price Estimates Lowered
1
Profit Margin
34.69
Relative Volume
0.63
Return on Equity vs Sector %
-5.6
Return on Equity vs Industry %
10.5
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.47
EBIT Estimation
602.8
◆
VRTX
Healthcare
$496.07
Swing / Pullback
Buy the dip on strong trends
WATCH
RSI
59.6
Range 1M
50%
Sup Dist
3.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
1.9%
EPS NY
13.3%
52W%
77.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+2.6% upside
Upside
+2.6%
Quality
87
MoS
9%
VRTX — P/E HistoricalBiotechnology
Vertex Pharmaceuticals IncorporSector: Healthcare
Industry: Biotechnology
Employees: 6400
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX
Latest News
—
Caricamento notizie per VRTX…
stock quote shares VRTX – Vertex Pharmaceuticals Incorporated Stock Price stock today
news today VRTX – Vertex Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch VRTX – Vertex Pharmaceuticals Incorporated yahoo finance google finance
stock history VRTX – Vertex Pharmaceuticals Incorporated invest stock market
stock prices VRTX premarket after hours
ticker VRTX fair value insiders trading